威高國際(01173.HK)中期虧損2232萬港元 同比收窄75.58%
格隆匯11月25日丨威高國際(01173.HK)公佈,截至2021年9月30日止6個月,公司實現營業額2.64億港元,同比增加15.44%;期內虧損2232萬港元,同比收窄75.58%;每股虧損0.886港仙。
回顧期內,零售店舖的營運仍受全球爆發的2019冠狀病毒病疫情影響。本地銷售緩慢復甦,帶動集團化粧品及時裝分類業務的營業額增加。
於2021年9月30日,集團共設有64間Colourmix及MORIMOR化粧品專門店(2020年9月30日:72間),其中58間位於香港,6間位於澳門。於回顧期內,集團的化粧品業務主要由地消費支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.